This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The post FDA Takes Step Toward Removal of Ineffective Decongestants From the Market appeared first on MedCity News. Use of this ingredient in cold and allergy medicines grew after a federal law required that pseudoephedrine-containing products be kept behind pharmacy counters.
The digital health fundraising market seems to be truly normalizing following the highs and lows of the pandemic, according to market research. The post Digital Health’s Funding Rebound Is Going Well, Market Research Shows appeared first on MedCity News. During the first half of this year, U.S. billion across 266 deals.
Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to a $5.4 Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to its $5.4 billion acquisition the New York pharma made two years ago.
When asked whether the startup is thinking about a public exit anytime soon, CEO Prashant Warie said that for now, the company’s focusing is on continuing to build its market globally and “venturing deeper into meeting the healthcare challenges of the U.S.” Snags $65M to Expand Its Presence in US Market appeared first on MedCity News.
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. 🤖 AI-Powered Tools: Learn about essential AI-driven features that assist marketing and sales professionals in automating tasks, analyzing data, and enhancing customer engagement. Be part of the conversation!
While Pfizer’s German mRNA partner BioNTech has high hopes for its post-COVID future, the company continues to feel the squeeze from the changeover to a seasonal vaccine market.
To meet evolving consumer expectations, providers must have a strong digital marketing strategy and user experience online. Here are 5 healthcare marketing trends to pay attention to in 2024.
The post AMA Report Details Low Competition in PBM Market appeared first on MedCity News. The American Medical Association released a new report on Monday on pharmacy benefit managers. It explained that there is low competition among PBMs and high vertical integration with payers.
Knowing where healthcare professionals are online, their preferred platforms, and what they do there is crucial for pharma marketers. The post Decoding the Digital Footprint of Healthcare Professionals: A Roadmap for Pharma Marketers appeared first on MedCity News.
This eBook highlights how data-driven strategies empower marketing campaigns through personalization tactics. Here’s what’s covered: How data-driven marketing drives the customer experience. Understanding marketing strategy & performance. The most challenging obstacles to data-driven marketing success.
The post Market Trends to Watch for Health Systems and Their Specialty Pharmacies appeared first on MedCity News. The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
It’s clear what should happen in a functioning drug pricing market federally and in California, but it is not happening today. The post Three Ways Drug Pricing Should Work in a Functioning Market, But Isn’t appeared first on MedCity News. We can’t wait for others to find a solution to high drug prices.
The post Evolving Markets, Innovative Solutions: The Rise of Specialty VBC appeared first on MedCity News. This new approach is helping payors and providers unlock new value from their VBC initiatives while offering more effective and condition-specific treatment for patients.
In this second of a two-part article, we’ll cover common obstacles and offer insights on how to overcome these barriers to achieve success in the healthcare market. The post Market Acceptance: Key Challenges for Health Tech appeared first on MedCity News.
As marketing becomes more tech-driven, the role of marketing operations (MOps) is getting more complex. Today, the discipline is increasingly interwoven with other vital go-to-market motions — including sales and customer support — and is responsible for all business elements associated with marketing, including the tech stack.
Given the link established across studies between marketing practices and the opioid overdose crisis, a few strategic steps can form a path forward for clinicians and policymakers.
Integrating digital tools will advance things even further and help marketers and MLR teams maintain brand consistency and ensure compliance across digital and content operations. The post Unify Digital Publishing with MLR Review to Speed Compliant Content to Market appeared first on MedCity News.
As data continues to play a starring role in today’s B2B organizations, both marketing and sales operations professionals are poised to solidify their place as critical revenue drivers.
Investing in strategic healthcare communications is not just good marketing, it is essential for organizations that want to restore trust and improve patient outcomes. The post The Role of Marketing in Building Trust Between Providers and Patients appeared first on MedCity News.
Meanwhile, the mostly stagnant biotech IPO pipeline is showing new signs of life with two large stock market debuts expected this week. The post A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets appeared first on MedCity News.
A hearing healthcare veteran consultant, who has significant hearing loss, describes 7 market-tested best practices. Understanding the consumer-patient journey is crucial to developing strategic priorities for companies across hearing healthcare, from hearing aids to cochlear implants to gene/drug therapy.
Morgan, which has doubled its market projection for GLP-1 diabetes and obesity treatments to $71 billion for 2032. The analysts project Novo and Eli Lilly will dominate the market. . | Promising heart data for Novo Nordisk's Wegovy are a "paradigm shift," according to J.P.
When times are tough and marketers are asked to do more with the same (or less), we have to make tough choices. Here are 7 creative ways marketers can work smarter (not harder) - with the resources you already have! However, you might be able to squeeze more value from the tools and processes you’re already using.
The post Illumina Spin-Off Now Complete, Grail Sets Out on Its Own on the Public Markets appeared first on MedCity News. While the separation from Illumina ends a protracted antitrust battle, Grail is still in the early stages of a long-term strategy to win regulatory validation and payor coverage for its multi-cancer early detection test.
The post Rapport’s Stock Market Debut Reaps $154M as Novel Epilepsy Med Heads for Mid-Stage Test appeared first on MedCity News. The new capital will support clinical development of a lead drug with a novel approach to focal epilepsy, a form of the disorder that affects 1.8 million people in the U.S.
The post What Does the Future of the Food-As-Medicine Market Look Like? During a webinar hosted by PitchBook, healthcare experts shared that the food-as-medicine space will likely see consolidation in the future, as well as advancements in technology and reimbursement. appeared first on MedCity News.
The FDA awarded marketing authorization for a new Invitae test that uses next-generation sequencing to assess multiple genes to identify variants indicating a person’s predisposition for certain cancers. The regulatory action creates a new regulatory classification making Invitae’s test the predicate device for future cancer tests.
Finding a vendor to cleanse and optimize your marketing database can be difficult if you don’t know what to look for. ZoomInfo has produced this eBook to help marketing leaders understand best practices around cost and value when it comes to choosing a B2B contact data provider. This buyer’s guide will cover: Buying Considerations.
The commercial market has struggled to adopt value-based care, but HealthPartners has had some success, according to Mark Hansberry, senior vice president and chief marketing officer of the company. During a conference, he shared five rules for scaling value-based care, including creating trust and providing real-time data.
Several years ago, Highmark began questioning its exclusive relationships with specialty pharmacies and started working with Free Market Health, which matches patients to the pharmacy that best fits their needs. The post Why This Health Plan Moved Away from Exclusive Relationships with Specialty Pharmacies appeared first on MedCity News.
Amylyx Pharmaceuticals is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial. Amylyx is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial.
The post Remodel Health Secures Over $100M to Fuel Expansion in the ICHRA Market appeared first on MedCity News. Remodel Health received $100 million in funding from Oak HC/FT and Hercules Capital.
It’s not a far stretch to suggest that the topic isn’t exactly what gets marketers excited in their day-to-day workflow. However, if lead generation, reporting, and measuring ROI is important to your marketing team, then data normalization matters - a lot. Well, marketers rely on this grouping to reach their goals.
Guardant Health’s Shield, a liquid biopsy that screens for colorectal cancer by analyzing a patient blood sample, will compete against stool-based tests already established in the market. The post With FDA Nod for Colorectal Cancer Screening, How Much Market Share Can Guardant’s Blood Test Get? appeared first on MedCity News.
Amylyx Pharmaceuticals co-CEO Justin Klee previously said the company would withdraw ALS drug Relyvrio from the market if it failed its Phase 3 clinical trial. The biotech has set an eight-week timeline to evaluate its next steps.
The post GSK’s Quest to Bring Myeloma Drug Back to the Market Stops for a Data Drop at ASCO appeared first on MedCity News. GSK’s Blenrep has pivotal clinical trial results showing the multiple myeloma therapy reduced the risk of disease progression or death by nearly 50%.
Sales and marketing leaders have reached a tipping point when it comes to using intent data — and they’re not looking back. More than half of all B2B marketers are already using intent data to increase sales, and Gartner predicts this figure will grow to 70 percent. The bad news?
The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. | The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales.
Baxter International plans to exit China’s intravenous fluids market, multiple local media outlets report, citing a letter to distributors. Baxter plans to exit China's IV fluids market as it faces tough local competition and as it redirects global IV supplies to the U.S. to cope with a post-hurricane shortage.
The results could help Lilly differentiate its product from Novo Nordisk’s in the increasingly competitive market of obesity medications. Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial.
GSK took Blenrep off the market last year after the multiple myeloma drug failed its confirmatory study. But GSK now says it has interim data showing Blenrep beat a blockbuster Johnson & Johnson drug in a head-to-head Phase 3 study testing it as an earlier line of therapy.
Any return to normalcy may seem far-off, but sales and marketing are on the front lines of restarting the economy. However, there’s no team better suited to lead that charge than the marketing department. Strategically aligning your systems and teams. Getting consensus on how to define “qualified leads”.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content